Effectiveness of the Use of Dexamethasone in Treatment of Coronavirus Infections: A Systematic Review by Munir, Muhammad Ardi et al.
518 https://www.id-press.eu/mjms/index
Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia
Open Access Macedonian Journal of Medical Sciences. 2020 Nov 16; 8(T1):518-521.
https://doi.org/10.3889/oamjms.2020.5489
eISSN: 1857-9655
Category: T1 - Thematic Issue “Coronavirus Disease (COVID-19)”
Section: Narrative Review Article
Effectiveness of the Use of Dexamethasone in Treatment of 
Coronavirus Infections: A Systematic Review
Muhammad Ardi Munir1,2*, Sarifuddin Sarifuddin3, Amirah Basry4 , Christin Rony Nayoan5, Astri Hardiyanti6, Asep Dwitama Cyio6
1Department of Bioethics, Humanities, and Social Health Science, Faculty of Medicine, Tadulako University, Palu, Indonesia; 
2Department of Orthopaedic and Traumatology, Faculty of Medicine, Tadulako University, Palu, Indonesia; 3Department of 
Pulmonology and Respiratory Medicine, Faculty of Medicine, Tadulako University, Palu, Indonesia; 4Department of Biochemistry, 
Faculty of Medicine, Tadulako University, Palu, Indonesia; 5Department of Pharmacology, Faculty of Medicine, Tadulako 
University, Palu, Indonesia; 6Medical Profession Program, Faculty of Medicine, Tadulako University, Palu, Indonesia
Abstract
BACKGROUND: WHO declared the coronavirus disease (COVID)-19 outbreaks as a worldwide pandemic in March 
2020. More than 1,500,000 confirmed cases have been diagnosed in more than 130 countries and regions, estimated 
to cause 93,000 deaths so far recorded on April 10, 2020. There is no vaccine or antiviral treatment for coronavirus.
METHODS: The literature sources from the research were obtained by searching for national and international 
journals. The journal is indexed in Google Scholar, PubMed, Science Direct, e-books, and others. Five journals were 
obtained, including a literature review, systematic review, and randomized controlled trials (RCT) discussing the use 
of dexamethasone in COVID-19 therapy, Middle East respiratory syndrome, and severe acute respiratory syndrome.
RESULTS: A study from Oxford University compared 2100 COVID-19 patients who received low and moderate 
potential dexamethasone at a dose of 6 mg/day for 10 days with 4300 COVID-19 patients who only received 
standard treatment for coronavirus infection. The results obtained in patients using ventilator mortality decreased 
from 40% to 28%, and patients using oxygen, the mortality rate decreased from 40% to 20%. The dexamethasone 
RCT study can reduce the death rate of 1 in 3 COVID-19 patients who received mechanical ventilation therapy and 
1 in 5 patients who received oxygen therapy without mechanical ventilation but did not reduce patients’ mortality rate 
who did not receive therapy oxygen.
CONCLUSION: The use of dexamethasone with oxygen therapy and mechanical ventilation can reduce mortality 
patients with COVID-19.
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Introduction
Coronavirus (CoV) is an RNA virus of 120–160 
nm particulate size. This virus infects mostly wildlife, 
including bats and camels. CoV is contagious with 
six types: Alphacoronavirus 229E, alphacoronavirus 
NL63, OC43 beta CoV, HKU1 beta-CoV, severe 
acute respiratory syndrome-CoV (SARS-CoV), and 
Middle East Respiratory CoV Syndrome (Middle East 
respiratory syndrome [MERS]-CoV) [1], [2].
In December 2019, due to an unknown virus, 
some patients in Wuhan, Hubei, China, were diagnosed 
with secondary pneumonia. From December 31, 2019, 
to January 3, 2020, there was a significant increase 
in cases marked by 44 cases reported. This disease 
has spread in separate provinces in China, Thailand, 
Japan, and South Korea for <1 month [3], [4].
The sample studied shows the etiology of 
a new type of CoV. The name of this disease was 
originally the 2019 novel CoV (2019-nCoV). The WHO 
revealed a new name on February 11, 2020, CoV 
Disease (COVID-19), which was caused by the CoV-2 
(SARS-CoV-2) extreme acute respiratory syndrome 
virus [5], [6].
In March 2020, the WHO proclaimed the 
COVID-19 epidemic a global pandemic. In more than 
130 countries and regions, more than 1,500,000 
confirmed cases are diagnosed, expected to cause 
93,000 casualties as recorded on April 10, 2020 [7].
SARS-CoV-2 can cause various symptoms, 
including fever, fatigue, dry cough, myalgia, and 
difficulty breathing. There is evidence that SARS-
CoV-2 variations have been produced from humans 
by respiratory outlets triggered by cough and 
sneezing [8]. There is no vaccine or antiviral treatment 
for CoV. Therefore, it is imperative to determine the 
treatment plan as soon as possible for the COVID-19 
outbreak [9], [10], [11].
Dexamethasone is a corticosteroid preparation. 
Corticosteroids have an outstanding inhibitory effect 
on inflammatory factors and are typically used 
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as an alternative treatment for viral pneumonia. 
Glucocorticoids are steroid hormones with anti-
inflammatory properties that block pro-inflammatory 
genes encoding cytokine, chemokine, cellular adhesion 
molecules, inflammatory enzymes, and inflammatory 
process receptors [12].
Dexamethasone was shown to be the first 
drug to prevent CoV deaths in more than 430,000 
patients worldwide, based on a randomized controlled 
clinical trial (randomized controlled trials [RCT]) study 
in the United Kingdom. Dexamethasone can decrease 
mortality by around one-third in patients with CoV 
infection ventilators in these tests [13], [14], [15]. Based 
on these problems, we are interested in conducting 
a literature review on the effectiveness of using 
dexamethasone in the treatment of CoV infections.
Methods
This literature uses the method of literature 
review. Sources from the research were obtained 
by searching for national and international journals. 
The journal is indexed in Google Scholar, PubMed, 
Science Direct, e-books, and others. Five bulletins 
were obtained, including a literature review, systematic 
review, and RCT discussing the use of dexamethasone 
in COVID-19 therapy, MERS, and SARS.
Results
In a recovery trial study in March 2020 
conducted at Oxford University, a RCT tested various 
potential therapies. The research compares 2100 
patients receiving low to moderate potential 6 mg a 
day dexamethasone for 10 days, with 4300 patients 
getting normal CoV treatment only. The findings found 
that dexamethasone had the most extraordinary effect 
relative to mildly ill people in seriously ill patients who 
used ventilators. The results of using dexamethasone 
in patients using a ventilator can reduce the risk of 
death from 40% to 28%. Dexamethasone also has an 
effect on patients taking oxygen therapy but not on the 
ventilator; an increase in mortality decreased from 40% 
to 20% [16].
Based on studies conducted by Chen et al., 
corticosteroids were administered to 401 SARS patients, 
in which there were 152 patients in the critical category. 
The results showed that corticosteroids reduced mortality 
and treatment time in acute SARS patients. Dose offered 
for <7 days is low-moderate (to 0.5–1 mg/kg body weight 
or equivalent of methylprednisolone) [17].
Built upon the RCT dexamethasone report, 
the mortality rate was reduced by 1 in 3 COVID-19 
patients receiving mechanical ventilation and by 1 in 5 
COVID-19 patients receiving oxygen therapy without 
mechanical ventilation, but mortality rates were not 
reduced in those without oxygen therapy [18], [19].
Table 1 shows the use of dexamethasone in 
the preliminary report and some guidelines that have 
used dexamethasone as a therapy in the treatment of 
COVID-19. 
Discussion
Since the first study was released in December 
2019, COVID-19 has gained worldwide interest 
because of its similarity to SARS-CoV and MERS-CoV 
in causing fatal respiratory illnesses and possibly 
contributing to significant human infections and their 
economic effects. The use of corticosteroid treatment 
is still under consideration in patients with SARS and 
MERS that are close to COVID-19 [24], [25].
Corticosteroid therapy of patients with SARS 
is used regardless of the early anecdotal knowledge, 
Table 1: Using dexamethasone
References Year Drug Trial and clinical experience Dosage
Horby Peters [20] 2020 Dexamethasone 
intravenous
A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 
patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 
days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75–0.93; p<0.001)
In the dexamethasone group, the incidence of death was lower than that in the usual care group among 
patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51–0.81) and 
among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% 
CI, 0.72–0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 
14.0%; rate ratio, 1.19; 95% CI, 0.91–1.55)
6 mg once daily 
for up to 10 day
Guidelines CHKD 
[21], [22]
2020 Dexamethasone 
intravenous and peroral
Dexamethasone should not be used in COVID-19 (+) patients who are: 
a) Otherwise healthy and do not require respiratory support 
Dexamethasone should be utilized in COVID-19 (+) patients with: 
a) Respiratory support (oxygen or invasive mechanical ventilation)
b)  An underlying condition requiring chronic steroid treatment, steroids should be continued
c) An additional diagnosis where steroid therapy is appropriate
0.15 mg/kg once 
daily (Max: 6 mg) 
Raymond [23] 2020 Dexamethasone In the RECOVERY trial, dexamethasone was beneficial for participants treated seven or more days into the 
symptomatic phase, with the onset of hypoxemia. Importantly, there was a non-significant trend (P=0.14) 
toward possible harm affecting participants without hypoxemia and not on mechanical ventilation. RECOVERY 
findings, therefore, support use of dexamethasone only for patients with hypoxemia, not those with milder 
disease. The data do not support the use of dexamethasone or other corticosteroids in the outpatient setting
6 mg/day
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and it is comparable of patients with acute respiratory 
distress syndrome (ARDS) to radiological and histologic 
observations in essential diseases [26], [27]. In March 
2003, the proposed high dose glucocorticoids should 
be used based on Chinese SARS treatment trials 
if the patient has a fever for more than three days 
or if radiological reports are indicative. Persistent 
pulmonary activity or gradual decline In Bronchiolitis 
obliterans, the radiographic picture with pneumonia 
and likeness of the histologic features to those of early 
ARDS in postmortem studies have prompted doctors in 
china use corticosteroids in combination with ribavirin 
for the treatment of SARS. In ARDS and particularly 
in Bronchiolitis obliterans with organizing pneumonia, 
corticosteroid therapy with ribavirin has been used 
with some success in the resolution of fever and lung 
opacities within two weeks [28].
Recovery trials conducted at Oxford University 
show that at the dose of dexamethasone tested, steroid 
treatment benefits may outweigh the potential harm 
posed. This research did not find any remarkable 
medication side effects. According to Anthonia, a 
deformed or hyperactive inflammatory reaction in 
patients with a ventilator leads to morbidity, mortality, 
and clear viral effects [13].
The corticosteroid partnership in SARS 
management may be complicated with acute lung 
injury (ALI)/ARDS. Excessive systemic inflammation 
has been identified in ARDS and B emission 
factors may lead to glucosteroid tolerance, which is 
related to relative adrenal insufficiency and further 
degradation of ARDS. Use methylprednisolone, 
which can be used to solve problems by recovering 
systemically. The present opinion thus indicates that 
ARDS steroid therapy can only be done on the basis 
of relative loss due to systemic inflammation and 
targeted at increasing systemic inflammation. The 
length of the steroid depends on the inflammatory 
length. In summary, appropriate advice for ALI/ARDS 
steroid administration involves the initialization of a 
sufficient steroid dosage at a time of relative adrenal 
insufficiency, discussed in terms of steroid application. 
Steroids need not, however, be delayed until ARDS 
continues [17], [29], [30].
Corticosteroids will dramatically reduce the 
concentrations of interleukin (IL)-8, monocyte protein-1, 
and induced protein-10 from days 5 to 8 after treatment. 
In further analysis, IL-10, IL-6, and tumor necrose 
(tumor necrosis factor [TNF]) levels were higher than 
average before intake. Corticosteroid treatment still 
decreases IL-10 but not IL-6 and TNF. The data show 
the benefits of steroid therapy in reducing the lungs’ 
reserve response and protection [28], [31].
They observed that corticosteroids, large 
doses of 2019-nCoV pneumonia such as secondary 
infections, long-term complications, and extended-
release of the virus were likely based on corresponding 
research. However, severe inflammation and 
cytokine-related lung injuries can rapidly cause 
progressive pneumonia in critically ill patients. Doctors 
of the Chinese Thoracic Community have formed a 
consensus of experts on pneumonia corticosteroids 
2019-nCoV. Under the expert’s agreement on the 
basics of use with corticosteroids to be discussed;(1) 
The role of corticosteroids in suppressing the production 
of dysregulated cytokines patient with pneumonia in 
2019-ncoV (2) Corticosteroid must be used with caution 
in a critically diseased patient with pneumonia in 2019-
ncoV; (3) with hypoxia patients [32].
Conclusion
The use of dexamethasone with oxygen 
therapy and mechanical ventilation can reduce mortality 
patients with COVID-19.
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